

In the Claims:

1 – 70. (Canceled)

71. (Currently Amended) A process for treating a ~~transplant~~ recipient of a transplant to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising

administering to a ~~transplant~~ recipient of a transplant mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against a xenoantigen to the effector cells, whereby in the ~~transplant~~ recipient the effector cells have a reduced immune response against the xenoantigen.

72. (Withdrawn) A process for reducing an immune response against an alloantigen, comprising contacting immune effector cells with at least one member selected from the group consisting of xenogeneic mesenchymal stem cells and a supernatant of xenogeneic mesenchymal stem cells in an amount effective to reduce the immune response.

73-95. (Canceled)

96. (Previously Presented) The process of claim 71 wherein said effector cells are T cells.

97. (Previously Presented) The process of claim 96 wherein the T cells are from the donor and the xenoantigen is from the recipient.

98. (Previously Presented) The process of claim 71 wherein the T cells are from the recipient and the xenoantigen is from the donor.

99. (Previously Presented) The process of claim 71 wherein said T cells are present in a transplant.

101. (Currently Amended) The process of claim 71 wherein said MSCs are administered to a ~~transplant~~ recipient of a transplant suffering from graft-versus-host disease.

102. (Previously Presented) The process of claim 71 wherein prior to said administration said mesenchymal stem cells (MSCs) have been expanded in culture.

103. (Previously Presented) The process of claim 71 wherein said effector cells are T cells previously activated and said immune response is the reactivation of said T cells.

104. (Previously Presented) The process of claim 71 wherein the transplant is skin.

105. (Currently Amended) The process of claim 71 wherein the mesenchymal stem cells are administered to the ~~transplant~~ recipient to treat rejection of the transplant by the recipient.

106. (Previously Presented) The process of claim 71 wherein the mesenchymal stem cells are human mesenchymal stem cells.

107. (Previously Presented) The process of claim 71 further comprising administering to the recipient immunosuppressive agents.

108. (Previously Presented) The process of claim 71 wherein the transplant is a solid organ.

109. (Previously Presented) The process of claim 108 wherein the solid organ is selected from heart, pancreas, kidney, lung or liver.

110. (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered prior to said transplant.

111. (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered concurrently with said transplant.

112. (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered as part of the transplant.

113. (Previously Presented) The process of claim 71 wherein the mesenchymal stem cells are administered subsequent to transplant.

114. (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered intravenously to the recipient.

115. (Previously Presented) The process of claim 71 wherein said effector cells are cells of a recipient of said donor transplant.

116. (Withdrawn) A process for treating a transplant recipient to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising:

transplanting to a transplant recipient a transplant treated with mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against a xenoantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the xenoantigen.

117. (Withdrawn) The process of claim 116 wherein said effector cells are T cells.